Aadi Bioscience (NASDAQ:AADI) Vs. TVTX, SUPN, PRTA, ISEE, DVAX, MORF, ZGNX, BCYC, TGTX, and ERAS
Should you be buying Aadi Bioscience stock or one of its competitors? The main competitors of Aadi Bioscience include Travere Therapeutics (TVTX), Supernus Pharmaceuticals (SUPN), Prothena (PRTA), IVERIC bio (ISEE), Dynavax Technologies (DVAX), Morphic (MORF), Zogenix (ZGNX), Bicycle Therapeutics (BCYC), TG Therapeutics (TGTX), and Erasca (ERAS). These companies are all part of the "pharmaceutical preparations" industry.
Aadi Bioscience vs.
Supernus Pharmaceuticals (NASDAQ:SUPN) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, community ranking, media sentiment and profitability.
Supernus Pharmaceuticals currently has a consensus target price of $39.50, indicating a potential upside of 34.86%. Aadi Bioscience has a consensus target price of $47.50, indicating a potential upside of 154.01%. Given Aadi Bioscience's higher probable upside, analysts plainly believe Aadi Bioscience is more favorable than Supernus Pharmaceuticals.
In the previous week, Supernus Pharmaceuticals had 5 more articles in the media than Aadi Bioscience. MarketBeat recorded 6 mentions for Supernus Pharmaceuticals and 1 mentions for Aadi Bioscience. Aadi Bioscience's average media sentiment score of 0.00 beat Supernus Pharmaceuticals' score of -0.38 indicating that Aadi Bioscience is being referred to more favorably in the news media.
Supernus Pharmaceuticals has higher revenue and earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Supernus Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
Supernus Pharmaceuticals has a net margin of 14.49% compared to Aadi Bioscience's net margin of 0.00%. Supernus Pharmaceuticals' return on equity of 10.56% beat Aadi Bioscience's return on equity.
99.6% of Supernus Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.5% of Aadi Bioscience shares are owned by institutional investors. 8.0% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 7.1% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Supernus Pharmaceuticals received 442 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 74.58% of users gave Supernus Pharmaceuticals an outperform vote while only 53.85% of users gave Aadi Bioscience an outperform vote.
Summary
Supernus Pharmaceuticals beats Aadi Bioscience on 12 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aadi Bioscience (NASDAQ:AADI) vs. Its Competitors
Aadi Bioscience Competitors List
